Gadopiclenol Patent Expiration
Gadopiclenol was first introduced by Guerbet
Gadopiclenol Patents
Given below is the list of patents protecting Gadopiclenol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Elucirem | US11590246 | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process | Jan 17, 2040 | Guerbet |
| Elucirem | US12064487 | Complex Of Gadolinium And A Chelating Ligand Derived From A Diastereoisomerically Enriched Pcta And Preparation And Purification Process | Jan 17, 2040 | Guerbet |
| Elucirem | US10973934 | Gadolinium bearing PCTA-based contrast agents | Aug 06, 2039 | Guerbet |
| Elucirem | US8114863 | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging | May 25, 2032 | Guerbet |
Gadopiclenol's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Gadopiclenol:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease | Guerbet | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Screening for Brain Metastases | University of Zurich | NA |
NOT YET RECRUITING
(Mar 1, 2026)
| PHASE2 |